血浆苯乙酰谷氨酰胺水平与缺血性卒中预后:基于CATIS试验的多中心前瞻性研究
该多中心前瞻性队列纳入3564例中国缺血性卒中患者,随访3个月,877例发生主要结局。基线血浆苯乙酰谷氨酰胺每升高500 ng/mL,主要结局、主要残疾和死亡风险分别增加7%、6%和6%;最高四分位组主要结局、主要残疾和死亡的OR/HR分别为1.62、1.62和2.59。
要点
- 基线血浆苯乙酰谷氨酰胺升高与缺血性卒中后3个月不良结局风险增加相关。
- 最高四分位组较最低四分位组主要结局OR 1.62(95%CI 1.18-2.23),死亡HR 2.59(95%CI 1.19-5.60)。
- 苯乙酰谷氨酰胺加入常规危险因素可改善主要结局的风险重分类(NRI 19.34%,IDI 0.23%)。
核心结论
- 基线血浆苯乙酰谷氨酰胺水平升高与缺血性卒中后3个月不良临床结局风险增加相关,提示其可能是有前景的预后生物标志物。
- 需要进一步研究以探讨苯乙酰谷氨酰胺是否为卒中特异性生物标志物。
研究设计与样本
- 多中心前瞻性队列研究,纳入来自CATIS(中国急性缺血性卒中抗高血压试验)的3564例中国缺血性卒中患者,随访至卒中发病后3个月。
主要发现
- 3个月随访期间,877例发生主要结局(死亡或主要残疾,改良Rankin量表评分3-6)。
- 多因素校正后,血浆苯乙酰谷氨酰胺每升高500 ng/mL,主要结局风险增加7%(P=0.012),主要残疾风险增加6%(P=0.016),死亡风险增加6%(P=0.028)。
- 最高四分位组较最低四分位组:主要结局OR 1.62(95%CI 1.18-2.23;Ptrend=0.001),主要残疾OR 1.62(95%CI 1.16-2.24;Ptrend=0.001),死亡HR 2.59(95%CI 1.19-5.60;Ptrend=0.025)。
- 苯乙酰谷氨酰胺四分位越高,3个月改良Rankin量表评分分布显著更差(Ptrend=0.003)。
- 多因素校正样条回归模型显示苯乙酰谷氨酰胺与主要结局呈线性关系(线性P<0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需要进一步研究以探讨苯乙酰谷氨酰胺是否为卒中特异性生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phenylacetylglutamine is implicated in platelet clotting and thrombosis, but its prognostic value in ischemic stroke remains unclear. We aimed to explore the associations of plasma phenylacetylglutamine levels with adverse outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS: Our multicenter prognostic cohort study included 3564 Chinese patients with ischemic stroke from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale score, 3-6) at 3 months after ischemic stroke. RESULTS: During 3 months of follow-up, 877 participants experienced the primary outcome. After multivariate adjustment, each 500 ng/mL increase of phenylacetylglutamine was associated with a 7% (P=0.012), 6% (P=0.016), and 6% (P=0.028) increased risk of the primary outcome, major disability, and death, respectively. The odds ratios or hazard ratios in the highest versus the lowest quartile of plasma phenylacetylglutamine were 1.62 ([95% CI, 1.18-2.23]; Ptrend=0.001) for the primary outcome, 1.62 ([95% CI, 1.16-2.24]; Ptrend=0.001) for major disability, and 2.59 ([95% CI, 1.19-5.60]; Ptrend=0.025) for death, respectively. There was a significantly worse shift in the distribution of modified Rankin Scale score at 3 months with higher phenylacetylglutamine quartiles (Ptrend=0.003). Multiple-adjusted spline regression model showed a linear relationship between phenylacetylglutamine and primary outcome (P value for linearity<0.001). The addition of plasma phenylacetylglutamine to conventional risk factors significantly improved the risk reclassification for the primary outcome (net reclassification improvement, 19.34%; P<0.001; integrated discrimination improvement, 0.23%; P=0.019). CONCLUSIONS: Elevated plasma phenylacetylglutamine levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that phenylacetylglutamine may be a promising prognostic biomarker for ischemic stroke. Further studies are needed to investigate whether phenylacetylglutamine is a stroke-specific biomarker.
引用
- He Y, Yang P, Shi M, et al. Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial. Stroke. 2024. PMID: 39466896. doi:10.1161/STROKEAHA.124.048494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。